FDA Rejects Ivonescimab

Slowing a tumor was not enough. The US Food and Drug Administration has declined to approve ivonescimab for a group of lung cancer patients because the drug did not show a statistically significant survival advantage, Summit Therapeutics said on November 15 after receiving a Complete Response Letter from the agency.

Ivonescimab: mechanism of action. Image credit: Summit Therapeutics
Ivonescimab: mechanism of action. Image credit: Summit Therapeutics

Key Takeaways

  • The application covered ivonescimab plus platinum chemotherapy for EGFR-mutant non-small cell lung cancer after prior TKI therapy.
  • The FDA said a progression-free survival gain without a significant overall survival benefit does not support a positive benefit-risk profile, according to Summit.
  • Summit says development continues, including two Phase III trials in first-line lung cancer.

What the Agency Decided

Summit sought approval for ivonescimab combined with platinum-containing chemotherapy. The intended patients have locally advanced or metastatic non-small cell lung cancer with EGFR mutations and have already received an EGFR tyrosine kinase inhibitor. The FDA's target date for a decision was November 14.

According to Summit, the letter says the application cannot be approved in its present form. The agency found that substantial evidence of effectiveness had not been established without a statistically significant improvement in overall survival.

“We are disappointed for patients and their families,” said Robert W. Duggan, Summit's chairman and co-chief executive. The company did not announce a resubmission plan or a timeline.

The Trial Behind the Application

The filing rested on HARMONi, a global, randomized, double-blind Phase III study. It compared ivonescimab plus chemotherapy with placebo plus chemotherapy in patients previously treated with a third-generation EGFR inhibitor.

The trial met its primary goal on progression-free survival, the time patients live without their cancer worsening. Overall survival showed a positive trend at the primary analysis but missed statistical significance. A later follow-up produced a hazard ratio of 0.76, which Summit says held across Asian and Western patients. That analysis was not the pre-specified test.

Safety results were broadly similar between the groups. Treatment-related discontinuations reached 7.3% with ivonescimab and 5.0% with placebo. Treatment-related deaths were 1.8% and 2.3%.

Ivonescimab is a bispecific antibody. One molecule blocks PD-1, an immune checkpoint, and VEGF, a signal that tumors use to grow blood vessels. Summit licensed the drug from China's Akeso in January 2023 and holds rights in the Americas, Europe, the Middle East, Africa and Japan. Akeso already sells it in China.

Stakes for Next-Generation Immunotherapy

Ivonescimab drew wide attention because earlier trials in China suggested it could outperform established PD-1 drugs, and other drugmakers have since pursued rival PD-1/VEGF antibodies. The US filing was always a harder case. The FDA agreed to review the application only after some pushback, with results in international patients less impressive than those seen in China. The rejection tells developers in this drug class that the agency expects survival evidence from global trials, a bar that matters as Chinese drugmakers supply a growing share of new cancer medicines.

For Summit, the decision delays US entry and shifts weight onto HARMONi-3 and HARMONi-7, its first-line lung cancer studies. The original HARMONi readout showed a 48% reduction in the risk of progression, a result that would have been enough for some earlier cancer approvals. Regulators have not turned uniformly cautious. The agency recently granted tentative approval to a generic HIV prevention shot, and other novel therapies are advancing on strong pivotal data, including Beam's base-edited sickle cell treatment. In oncology, the message from this letter is that delaying progression is no longer sufficient on its own.

Written by Alius Noreika